Brawn Biotech share price
You have to be logged in to add this to Watchlist.- ₹18.60(-4.96%)July 18, 2025 15:15:00 PM IST
- NSE
- BSE
- Vol : 0.11K (NSE + BSE)Last 20 day avg : 0.89 K
Brawn Biotech is trading -4.96% lower at Rs 18.60 as compared to its last closing price. Brawn Biotech has been trading in the price range of 19.57 & 18.60. Brawn Biotech has given -8.17% in this year & 7.17% in the last 5 days. The company posted a net profit of -0.49 Crores in its last quarter.Listed peers of Brawn Biotech include Ganga Pharmaceuticals (-%), Brawn Biotech (-4.96%), Tiaan Consumer (4.95%).The Mutual Fund holding in Brawn Biotech was at 0.35% in 30 Jun 2025. The MF holding has decreased from the last quarter. The FII holding in Brawn Biotech was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 20, 2025, 09:38 AM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/B1.78The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.13Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To Equity-The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable- The company's revenue fell during March quarter by 34.45% from Rs 3.45 crore to Rs 2.26 crore, year-on-year
- The company has increased its March quarter loss by 1008.35% from Rs 0.04 crore to Rs 0.49 crore, year-on-year
- Earnings are insufficient to cover the interest expenses on outstanding debt
- R1
- 19.42
- R2
- 21.36
- R3
- 22.57
- S1
- 16.27
- S2
- 15.06
- S3
- 13.12
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Ganga Pharmaceuticals | Moderately Bearish | 13.32 | - | 6.44 | 111.00 | 0.9 | - | 3.25 |
| Brawn Biotech | Moderately Bullish | 18.60 | -4.96 | 5.58 | - | 1.7 | - | - |
| Tiaan Consumer | Neutral | 5.30 | 4.95 | 11.85 | 160.67 | 0.71 | - | 35,817.13 |
| Hemo Organic | Bearish | 9.06 | -4.93 | 3.14 | 21.34 | - | - | |
| Kobo Biotech | Bearish | 2.46 | -1.99 | 5.86 | - | - | - |
Promoter(s) holds a high stake in the company at 53.66%- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are not invested in this company
- Mutual Funds holding is constant over the last quarter at 0.35%
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-26 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-14 | Quarterly Results |
| 2024-08-14 | Quarterly Results |
| 2024-05-29 | Audited Results |
- IndustryBiotechnology & Drugs
- ISININE899B01015
- BSE Code530207
- NSE Code
Brawn Biotech is trading at 18.60 as on Fri Jul 18 2025 09:45:00. This is -4.96% lower as compared to its previous closing price of 19.57.
The market capitalization of Brawn Biotech is 5.58 Cr as on Fri Jul 18 2025 09:45:00.
The 52 wk high for Brawn Biotech is 26.05 whereas the 52 wk low is 15.46
Brawn Biotech can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 22.39
- Dividend Yield: 0.00%
- D/E ratio: -
Brawn Biotech reported a net profit of -1.80 Cr in 2025.
The Mutual Fund Shareholding was 0.35% at the end of 30 Jun 2025.